Trials / Completed
CompletedNCT02748057
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)
A Phase III, Open-label, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Rosuvastatin Monotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study will assess the safety and tolerability of Ezetimibe 10 mg+ Rosuvastatin 2.5 mg and Ezetimibe 10 mg+ Rosuvastatin 5.0 mg for up to 52 weeks in Japanese participants with hypercholesterolemia uncontrolled with monotherapy of Ezetimibe 10 mg or Rosuvastatin up to 5 mg.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ezetimibe | |
| DRUG | Rosuvastatin |
Timeline
- Start date
- 2016-05-18
- Primary completion
- 2017-12-11
- Completion
- 2017-12-11
- First posted
- 2016-04-22
- Last updated
- 2024-05-16
- Results posted
- 2018-12-04
Source: ClinicalTrials.gov record NCT02748057. Inclusion in this directory is not an endorsement.